Ultomiris Insurance Denied? Appealing Ravulizumab Coverage for PNH or aHUS

Ultomiris (ravulizumab-cwvz) is a next-generation terminal complement inhibitor from AstraZeneca (Alexion) that builds on the established mechanism of its predecessor, Soliris (eculizumab). Where Soliris requires infusions every two weeks, Ultomiris requires infusions only every eight weeks — a significant practical advantage for patients managing rare chronic conditions. Ultomiris is FDA-approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Despite these approved indications, insurance denials are common. Some insurers prefer Soliris because it has a longer track record; others require step therapy or apply excessive Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria. Whatever the reason, a denial for Ultomiris can be challenged.

Why Insurers Deny Ultomiris

Preference for Soliris. Some insurers maintain Soliris as the preferred complement inhibitor and require step therapy through Soliris before approving Ultomiris, even though both drugs have the same mechanism and Ultomiris offers the clinical advantage of less frequent dosing.

"Experimental" classification. Though Ultomiris received FDA approval in 2018 for PNH, some insurer policies lag behind and may not yet have updated policies reflecting all expanded indications.

Transition denials. Patients who were stable on Soliris and whose physicians recommended switching to Ultomiris for less frequent dosing may face denials on the grounds that their current treatment is working. This ignores the legitimate clinical reasons for transition, including reduced infusion burden and improved quality of life.

Diagnosis verification. As with Soliris, PNH and aHUS diagnoses require specialized testing, and denial pending diagnostic confirmation is common. Ensure all required testing has been documented.

Off-label use. Any use outside the four FDA-approved indications (PNH, aHUS, gMG, NMOSD) may be denied. Confirm the specific indication matches the label.

Cost-based scrutiny. Ultomiris carries annual costs comparable to Soliris (over $400,000), triggering intense utilization management scrutiny at commercial insurers.

FDA Approval Status

Ultomiris received FDA approval for PNH on December 21, 2018, and was subsequently approved for aHUS in 2019, for gMG in 2023, and for NMOSD in 2023. The PNH and aHUS approvals were based on Phase 3 trials (ALXN1210-PNH-301 and ALXN1210-aHUS-311) demonstrating non-inferiority to Soliris on efficacy endpoints with the advantage of less frequent dosing.

Ultomiris holds FDA Orphan Drug Designation for PNH, aHUS, gMG, and NMOSD. In your appeal, cite the FDA approval date and Orphan Drug Designation for the specific indication and directly rebut any "experimental" characterization.

Building Your Appeal

Specialist letter of medical necessity. Your hematologist, nephrologist, or neurologist should document the confirmed diagnosis (with supporting diagnostic tests), disease severity and history, prior treatment history (including any prior Soliris use), and the clinical rationale for Ultomiris specifically — particularly the advantage of reduced infusion frequency for your clinical situation.

Diagnostic documentation. For PNH: flow cytometry showing GPI-deficient red blood cells and/or granulocytes. For aHUS: exclusion of TTP, STEC-HUS, documentation of ADAMTS13, genetic testing where available. For gMG: anti-AChR or anti-MuSK antibody positivity, MGFA classification. For NMOSD: AQP4-IgG serostatus.

Non-inferiority trial data. The Phase 3 trials published in Blood and NEJM Evidence demonstrated that Ultomiris is non-inferior to Soliris with significantly less frequent dosing. This data supports both the clinical equivalence and the quality-of-life advantage of Ultomiris.

Step therapy rebuttal. If Soliris is required as a prior step, address this directly. If the patient was previously on Soliris and their physician is recommending Ultomiris for clinical reasons, document the transition rationale including infusion burden, patient preference, and clinical equivalence.

Specialty society guidance. International guidelines from the PNH Interest Group, the European Hematology Association, and the American Society of Nephrology support eculizumab/ravulizumab use for complement-mediated rare diseases. Cite relevant guidelines.

Expedited Review

PNH and aHUS can cause life-threatening hemolytic crises, thrombosis, and acute renal failure. If a patient is experiencing active disease or has recently been hospitalized, request expedited review with physician documentation of clinical urgency. Federal law requires a 72-hour decision on expedited appeals.

External Independent Review: Complete Guide" class="auto-link">External Review

After exhausting internal appeals, external review provides an independent clinical assessment. For FDA-approved rare disease treatments with Orphan Drug Designation and strong clinical trial data, external review overturns denials at meaningful rates. File within the deadline specified in your denial notice.

Patient Assistance Programs

AstraZeneca's Alexion OneSource program provides insurance navigation, co-pay assistance, and free drug for eligible patients. This program can provide access to Ultomiris while your appeal is pending. Contact Alexion patient support immediately upon denial.

NORD provides financial assistance and rare disease advocacy. The Aplastic Anemia and MDS International Foundation and the PNH Alliance offer peer support and insurance navigation help for PNH patients specifically.

Fight Back With ClaimBack

A denial for Ultomiris, a life-sustaining therapy for rare complement-mediated diseases, is a serious matter that demands a serious response. ClaimBack helps patients build compelling insurance appeals backed by clinical evidence, FDA documentation, and knowledge of your rights.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied